Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication for the treatment of PsA. The recommended dose is 30 mg BID
Certolizumab pegol (Cimzia®) gained FDA approval in September/October 2013 for two new indications, adults with active psoriatic arthritis (PsA) and adults with active ankylosing spondylitis (AS).
Screening for latent TB in patients with inflammatory arthritis who will be starting TNFα inhibitors is important to prevent complications of TB-reactivation. However, currently there is no ‘gold standard’ for the diagnosis of latent TB.
Estimates of the prevalence of psoriatic arthritis among individuals with skin psoriasis have varied in the literature from between 2% to more than 40%, depending on the method of ascertainment and case definition used to define psoriatic arthritis.
Approval for golimumab (which will by marketed under the trade name Simponi) was granted this week by the U.S. Food and Drug Administration. The drug received approval for the treatment of moderate to severe RA (in conjunction with methotrexate), active psoriatic arthritis (as monotherapy or with methotrexate), and active ankylosing spondylitis at a dose of […]